Effect of bevacizumab on acetic acid–induced ulcerative colitis in rats

Basit Öğe Kaydı
dc.authorid0000-0002-3834-3864
dc.contributor.authorÖzsoy, Zeki
dc.contributor.authorÖzsoy, Şeyma
dc.contributor.authorGevrek, Fikret
dc.contributor.authorDemir, Emre
dc.contributor.authorBenli , İsmail
dc.contributor.authorDaldal, Emin
dc.contributor.authorYenidoğan, Erdinç
dc.date.accessioned2019-05-10T09:39:05Z
dc.date.available2019-05-10T09:39:05Z
dc.date.issued2017
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü
dc.description.abstractBackground The aim of this study was to examine the effect of intraperitoneally administered bevacizumab on colitis induced by acetic acid. Methods An experimental model of acetic acid–induced colitis was introduced in rats. After the induction of colitis, bevacizumab was administered intraperitoneally at two different daily doses of low (2.5 mg/kg) or high (5 mg/kg) concentration. Control groups were included for colitis and bevacizumab. After 7 d, the rats were sacrificed, and colonic tissues were harvested for macroscopic and microscopic examination of colonic damage. Tumor necrosis factor alpha, interleukin 1 beta (IL-1?), IL-6, myeloperoxidase, malondialdehyde, glutathione, and superoxidismutase values were measured biochemically. Results There was no statistically significant macroscopic improvement in damage to the colon tissues (P > 0.05). The severity of inflammation was significantly reduced (0.98 ± 0.22) in the low-dose bevacizumab–treated rat group compared with the control group (P < 0.001). The decrease in the inflammation score in the high-dose bevacizumab–treated rat group was not statistically significant (1.40 ± 0.33). In addition, although there was no significant change in the myeloperoxidase levels biochemically, IL-6 and malondialdehyde levels decreased in the low-dose treatment group (P = 0.014, P = 0.002, respectively). A significant decrease was found at both treatment doses in IL-1? (P < 0.001, P = 0.010), tumor necrosis factor alpha (P < 0.001, P = 0.015), superoxidismutase (P = 0.046, P = 0.011), and glutathione (P = 0.012 and P < 0.001) levels. Conclusions Both treatment doses of bevacizumab were observed to have a protective effect in an experimental colitis model, and the dosage of 2.5 mg/kg bevacizumab was found to have a more prominent effect. © 2017 Elsevier Inc.
dc.identifier.citationOzsoy, Z., Ozsoy, S., Gevrek, F., Demir, E., Benli, I., Daldal, E., & Yenidogan, E. (2017). Effect of bevacizumab on acetic acid–induced ulcerative colitis in rats. journal of surgical research, 216, 191-200.
dc.identifier.doi10.1016/j.jss.2017.05.011
dc.identifier.endpage200en_US
dc.identifier.issn0022-4804
dc.identifier.scopusqualityQ1
dc.identifier.startpage191en_US
dc.identifier.urihttps://doi.org/10.1016/j.jss.2017.05.011
dc.identifier.urihttps://hdl.handle.net/11491/605
dc.identifier.volume216en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAcademic Press Inc.
dc.relation.ispartofJournal of Surgical Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBevacizumaben_US
dc.subjectRatsen_US
dc.subjectTreatmenten_US
dc.subjectUlcerative Colitisen_US
dc.titleEffect of bevacizumab on acetic acid–induced ulcerative colitis in rats
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu